A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)
This double-blind, randomized, placebo-controlled phase III trial studies how well treatment with omecamtiv mecarbil/AMG 423 works compared to a placebo in subjects with chronic Heart Failure with reduced ejection fraction (HFrEF).
Contact site for start date.
Location: CPMC (San Francisco)
Please contact Clinicalresearch@sutterhealth.org about the GALACTIC Study.
View study details on ClinicalTrials.gov
Subjects, 18 y/o and older, with history of chronic heart failure (HF), left ventricular ejection fraction (LVEF) ≤ 35%, NYHA class II to IV, hospitalized for HF currently or within one year, with elevated BNP or NT-proBNP.
Active, Not Recruiting
June 01, 2018
Investigator(s): Andrew Hudnut, MD